PRELIMINARY PROGRAMME

Replacement therapies in hemophilia A and B
Efficacy of extended half-life products

08.30

Real life data: real benefit. What have we achieved?
Pratima Chowdari (UK)

09.00

How to optimize the use of extended half-life product (PK analysis)
Alfonso Iorio (Canada)

Safety of replacement therapies (standard and novel) (part I)

09.30

How safety of novel anti-hemophilic drugs should be approached. Known and unknown adverse effects
Flora Peyvandi (Italy)

10.00

Are Fc – FVIII products less immunogenic? Any new clinical data?
Christoph Königs (Germany)

10.30

Break

Safety of replacement therapies (standard and novel) (part II)

11.00

Long-term side-effects of pegylated products: facts or fancies?
TBA

11.30

European pharmacovigilance of new products (with special emphasis on pegylated products)
Anneliese Hilger (EMA, Germany)

12.00

Immunogenicity of subcutaneous and intravenous drugs
David Lillicrap (Canada)

12.30

Industry Lecture
TBA

13.00

Lunch

14.00

Industry Symposium
TBA

15.00

Oral Communications

16.00

Choice of assays for novel anti-hemophilic therapies
Armando Tripodi (Italy)

16.30

Break

The role of von Willebrand factor in factor VIII immunogenicity

17.00

FVIII peptide presentation to the immune system by VWF modulation
Jan Voorberg (Netherlands)

17.30

High VWF affinity FVIII and immunogenicity
Peter Lenting (France)

18.00

Walking Poster Session